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University Hospitals, Brighton, and Stoke-on-Trent, United KingdomBackground The performance of emerging transcatheter aortic valve implantation (TAVI) clinical prediction models
(CPMs) in national TAVI cohorts distinct from those where they have been derived is unknown. This study aimed to investigate
the performance of the German Aortic Valve, FRANCE-2, OBSERVANT and American College of Cardiology (ACC) TAVI
CPMs compared with the performance of historic cardiac CPMs such as the EuroSCORE and STS-PROM, in a large national
TAVI registry.
Methods The calibration and discrimination of each CPM were analyzed in 6676 patients from the UK TAVI registry, as
a whole cohort and across several subgroups. Strata included gender, diabetes status, access route, and valve type.
Furthermore, the amount of agreement in risk classification between each of the considered CPMs was analyzed at an
individual patient level.
Results The observed 30-day mortality rate was 5.4%. In the whole cohort, the majority of CPMs over-estimated the risk of
30-day mortality, although the mean ACC score (5.2%) approximately matched the observed mortality rate. The areas under
ROC curve were between 0.57 for OBSERVANT and 0.64 for ACC. Risk classification agreement was low across all models,
with Fleiss's kappa values between 0.17 and 0.50.
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hDespite surgical aortic valve replacement (SAVR) being
the definitive treatment strategy for severe symptomatic
aortic stenosis, a significant proportion of patients are not
offered surgery due to co-morbidities or frailty that
contribute to high surgical risks and adverse outcomes in
such patient groups.1 Transcatheter aortic valve implanta-
tion (TAVI) has emerged as an efficacious but less invasive
treatment option in high and intermediate operative risk
patients.2-5 As such, treatment allocation between medical
management, SAVR and TAVI depends on multiple factors,
but key is the assessment of the patient's procedural risk.
Clinical predictionmodels (CPMs),which quantify the risks
associated with the proposed treatment strategy at an
individual patient level, can aid heart-teams in this clinical
decision-making process and are vital for audit purposes
between TAVI centers.
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Month 2016Cardiac surgery CPMs for short-term mortality predic-
tion, such as the EuroSCORE6,7 and the Society of Thoracic
Surgeons Predicted Risk of Mortality (STS) model,8 have
been used to identify high-risk patients in randomized trials
of TAVI.2,3 However, these surgical CPMs perform poorly
in predicting risk after both SAVR and TAVI, as exemplified
in the PARTNER cohort A trial where there was large
disagreement between the observed and STS-expected
30-day mortality.3 Moreover, several cohort studies have
shown the inaccuracy of the surgical CPMs in predicting
mortality after TAVI.9-11
Consequently, TAVI specific CPMs are beginning to
emerge from large cohorts of TAVI patients.12-15 In
particular, the German Aortic Valve Score (German AV)
was developed using patients who underwent either
surgical replacement or TAVI,13 while TAVI-specific CPMs
have been derived in the France TAVI registry (FRANCE-2
model),14 the Italian TAVI registry (OBSERVANT model)12
and the Society of Thoracic Surgeons/American College of
Cardiology Transcatheter Valve Therapy registry (ACC
model).15 However, the performance of the aforemen-
tioned TAVI-CPMs in large cohorts of patients outside of
their derivation cohorts is unknown. Hence, it is unclear if
they can be reliably used in other national settings.
Therefore, the aim of this study was to investigate the
performance and agreement of the German AV, FRANCE-2,
OBSERVANT and ACC TAVI-CPMs for predicting 30-day
mortality outside their development cohorts, to examine if
the performance was sufficient for them to be used for this
purpose. The study compared the TAVI-CPM performance
against surgical CPMs, namely the Logistic EuroSCORE
(LES), EuroSCORE II (ESII) and STS score.
Methods
UK TAVI registry
Prospectively collected data on every TAVI procedure
in the United Kingdom from January 2007 to December
2014 were obtained through the UK TAVI registry.16 By
the end of 2014, 34 UK centers were performing TAVI
procedures with multi-disciplinary teams of cardiologists,
surgeons and other healthcare professionals at each
center deciding on patients' suitability for TAVI.16 The
Web-based registry comprises 95 variables detailing
patient demographics, risk factors for intervention,
procedural details and adverse outcomes up to the time
of hospital discharge. All-cause mortality tracking was
obtained from the Office for National Statistics providing
the life-status of English and Welsh patients (two
countries of the UK). Mortality tracking was unavailable
for patients in Northern Ireland and Scotland and, as
such, these patients were removed from the analysis.
Statistical analysis
Multiple imputation was used for missing values, with
ten datasets imputed.17 Missing life-status was notimputed and this analysis excluded any patient who had
such a missing endpoint. To avoid underestimation of
covariate-outcome associations, 30-day mortality indica-
tion was used in the imputation models for missing
covariates.18 Further details of the imputation procedure
are given in the supplementary material.
The risk of 30-day mortality implied by each CPM was
retrospectively calculated for each patient based on the
published regression coefficients.6-8,12-15 This analysis used
clinical reasoning tomake assumptions regarding translation
between variable definitions in the published CPMs and
those in the UK TAVI dataset. Any CPM risk-prediction
variable that was not recorded in the UK TAVI registry was
assumed risk factor absent for all patients. The full translation
between each CPM and the TAVI registry variables is given
in the supplementary material (Supplementary Tables I–VII)
along with the statistical code used to calculate the scores.
The performance of each CPM was assessed in terms of
calibration and discrimination. Calibration is the agreement
between the expected and observed event rates across the
full risk range; discrimination is the ability of the CPM to
distinguish between those who will experience an event
and those who will not. Discrimination of the risk models
was analyzed using the area under the receiver operating
characteristic (ROC) curve, with values between 0.5 and 1
where higher values indicate better discrimination.
To examine the calibration of each CPM, a logistic
regression model was fitted with the event indicator as
the outcome and the linear predictor from the CPM as the
only covariate.19 Perfect calibration would occur when the
corresponding intercept and slope are zero and one
respectively, with the intercept estimated assuming a slope
of unity. Furthermore, the Brier Scorewas used as ameasure
of overall performance, with values between 0 (perfect
prediction) and 1 (worst prediction).20 CPM performance
was analyzed in the whole cohort and within several
subgroups. The following subgroups were considered: age
(≤orN75), sex, diabetes status, access route (transfemoral vs
non-transfemoral), valve type (SAPIEN vs CoreValve),
previous coronary artery bypass graft status, left ventricular
(LV) function (LV ejection fraction [LVEF] b50% or LVEF
≥50%), and procedure urgency (elective vs non-elective).
Patient-level risk agreement between CPMswas analyzed
in the surgical models and the TAVI models separately to
facilitate fair comparisons. It was decided, a priori, to
derive cut-off values for each CPM that defined three risk
levels (low-, medium- and high-risk), with approximately
equal patient numbers in each. The proportions of patients
forwhom risk classification agreedbetweenmultiple CPMs
was then calculated. In addition, Fleiss's κwas calculated in
the surgical and TAVI models.21 A sensitivity analysis was
conducted in which the risk stratifications were re-defined
to give a population ratio of 1:3:1 for low, medium, and
high risk, respectively.
R version 3.3.122 was used for all statistical analyses.
Multiple imputation of the dataset was completed using
Table I. Summary statistics, before multiple imputations of the missing data, of baseline and procedural characteristics in the UK TAVI dataset
Variable Summary (% of n = 6676) Missing (% of n = 6676)
Age, mean [range] 81.3 [29–101] 0 (0%)
Women, n (%) 3085 (46.2%) 22 (0.3%)
Weight (kg), mean [range] 74.0 [32.0–190.0] 131 (2.0%)
Height (m), mean [range] 1.6 [1.1–2.4] 159 (2.4%)
NYHA 42 (0.6%)
Class I, n (%) 185 (2.8%)
Class II, n (%) 1116 (16.7%)
Class III, n (%) 4186 (62.7%)
Class IV, n (%) 1147 (17.2%)
Creatinine, μmol/L, mean [range] 114.3 [29.0–1044.0] 73 (1.1%)
Creatinine greater than 200 μmol/L, n (%) 379 (5.7%) 73 (1.1%)
LVEF 59 (0.88%)
≥50%, n (%) 4074 (61.0%)
30–49%, n (%) 1929 (28.9%)
b30%, n (%) 614 (9.2%)
Extracardiac arteriopathy, n (%) 1572 (23.5%) 88 (1.3%)
Diabetes 35 (0.52%)
Dietary control, n (%) 290 (4.3%)
Oral medicine, n (%) 884 (13.2%)
Insulin, n (%) 363 (5.4%)
Dialysis, n (%) 127 (1.9%) 66 (0.99%)
MI 33 (0.49%)
Within 90 days of TAVI, n (%) 153 (2.3%)
Within 30 days of TAVI, n (%) 65 (0.97%)
Within 24 hours of TAVI, n (%) 6 (0.09%)
Procedure urgency 7 (0.10%)
Elective, n (%) 5853 (87.7%)
Urgent, n (%) 772 (11.6%)
Emergency, n (%) 35 (0.52%)
Salvage, n (%) 9 (0.13%)
Valve type 31 (0.46%)
Edwards SAPIEN Valve, n (%) 3684 (55.2%)
Medtronic CoreValve, n (%) 2735 (41.0%)
Access route 13 (0.19%)
TF access, n (%) 4965 (74.4%)
Transapical access, n (%) 1064 (15.9%)
Chronic lung disease, n (%) 1879 (28.1%) 94 (1.4%)
Cerebrovascular disease, n (%) 1139 (17.1%) 35 (0.52%)
Previous cardiac surgery, n (%) 2087 (31.3%) 35 (0.52%)
Critical preoperative state, n (%) 110 (1.6%) 81 (1.2%)
PA systolic N60 mmHg 785 (11.8) 1860 (27.9%)
LMS N50% or Triple vessel disease, n (%) 887 (13.3%) 74 (1.1%)
LMS, Left main stem disease; MI, myocardial infarction; NYHA, New York Heart Association Functional Classification; PA, pulmonary artery; TF, transfemoral access route.
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Volume 184, Number 0the mice package,23 graphical plots were made using the
ggplot2 package24 and the package pROC was used for
constructing ROC curves.25
The Health e-Research Centre, funded by the Medical
Research Council [MR/K006665/1] and the North Staf-
fordshire Heart Committee supported this work. The
authors are solely responsible for the design and conduct
of this study, all study analyses, the drafting and editing of
the manuscript, and its final contents.Results
The UK TAVI registry included all 7431 patients who
underwent a TAVI procedure between January 2007 and
December 2014. All patients from Northern Ireland (n =400) and the majority of Scottish patients (n = 193) were
excluded from the analysis due to absence of Office for
National Statistics mortality tracking. Out of the remain-
ing 6838 patients, a further 162 were removed due to
missing life status, leaving 6676 patients studied in this
analysis. The observed survival rates were 94.6%, 83.3%
and 64.4% at 30-day, 1-year, and 3-year follow-up,
respectively. Table I presents summary statistics for
baseline characteristics of the patients in the UK TAVI
registry.
Performance analysis
From January 2007 to December 2014, there were 360
deaths within 30-days of the TAVI procedure (5.4%). The
expected 30-day mortalities in the whole cohort were
Table II. Absolute and relative differences of the expected to observed 30-day mortalities
Risk model Expected 30-day mortality (%) Absolute difference to observed mortality⁎ Relative difference to observed mortality† (%)
LES 21.9 16.5 405.6
ESII 8.1 2.7 150.0
STS 5.1 0.3 94.4
German AV 7.4 2.0 137.0
FRANCE-2 9.2 3.8 170.4
OBSERVANT 7.1 1.7 131.5
ACC TAVI 5.2 0.2 96.3
⁎Calculated as the absolute value of expected minus observed.
†Calculated as (expected/observed) ×100.
Figure 1
Temporal changes in observed and expected mortality over each of the CPMs.
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Month 201621.9%, 8.1%, 5.1%, 7.4%, 9.2%, 7.1%, and 5.2% from the
LES, ESII, STS, German AV, FRANCE-2, OBSERVANT, and
ACC CPMs, respectively (Table II). The ACC score and
STS model were the closest to the observed mortality in
terms of absolute and relative differences, while the LES
overestimated risk by a factor of four (Table II). After a
decrease from 2007 to 2008, the observed 30-day
mortality per year remained approximately constant,
with further decreases in 2013 and 2014 (Figure 1). In
contrast, the profile of the majority of CPMs remained
approximately constant throughout (Figure 1). The
inflated observed 30-day mortality in the first two years
likely reflects the UK learning curve and advances in TAVI
technology, while the CPMs do not account for such
factors. The observed and expected 30-day mortality rates
over each subgroup are given in Supplementary Table VIII.Table III shows the performance of each CPM in the
whole cohort. While the calibration intercepts of the ACC
and STS models were significantly close to zero (ie, the
observed and expected mortalities agreed), the 95% CIs
for the calibration slopes did not span one, indicating
model miscalibration. Poor discrimination was observed,
with area under the ROC curves between 0.57 and 0.64
for the whole cohort; the FRANCE-2 TAVI score and the
ACC TAVI score had the highest AUC values of 0.62 and
0.64, respectively. Overall performance, as measure by
the Brier score, was similar for the majority of models
with values of 0.05; a Brier score of 0.09 for the LES was
the highest (worst) amongst the models. Quantitatively
similar results were obtained from a sensitivity analysis
that excluded patients who underwent TAVI in 2007 or
2008 (n = 337) where the observed mortality was
Table IV. Cut-off values and the pairwise κ values for the surgical and TAVI based CPMs
CPM Low risk⁎ High risk⁎ Fleiss's κ†
Surgical based LES ESII STS German AV
LES ≤14% N24% n/a 0.50 0.29 0.34
ESII ≤4% N8% 0.50 n/a 0.34 0.27
STS ≤3% N5% 0.29 0.34 n/a 0.47
German AV‡ ≤4% N8% 0.34 0.27 0.47 n/a
TAVI based German AV FRANCE-2 OBSERVANT ACC
German AV‡ ≤4% N8% n/a 0.17 0.13 0.26
FRANCE-2 ≤6% N10% 0.17 n/a 0.14 0.33
OBSERVANT ≤4.5% N9% 0.13 0.14 n/a 0.18
ACC ≤3% N5% 0.26 0.33 0.18 n/a
⁎All cut-off values were chosen to give approximately equal numbers of patients in low-, medium- and high-risk categories. Patients with predicted risks between the low- and high-risk
cut-off values were classified as medium risk.
†Values give the pairwise agreement between the two indicated CPMs.
‡ The German AV model was derived in a cohort with both surgical and TAVI patients and, thus, is considered in both groups of models.
Table III. Calibration, discrimination and Brier score for 30-day mortality in the whole cohort
Risk model Calibration intercept (95% CI)⁎ Calibration slope (95% CI) AUC (95% CI) Brier score
LES −1.75 (−1.86, −1.64) 0.35 (0.23, 0.48) 0.57 (0.54, 0.61) 0.093
ESII −0.47 (−0.59, −0.36) 0.40 (0.28, 0.53) 0.59 (0.55, 0.62) 0.054
STS 0.07 (−0.04, 0.18) 0.56 (0.42, 0.71) 0.60 (0.57, 0.63) 0.051
German AV −0.36 (−0.47, −0.25) 0.44 (0.32, 0.57) 0.59 (0.56, 0.62) 0.053
FRANCE-2 −0.60 (−0.71, −0.49) 0.69 (0.53, 0.86) 0.62 (0.59, 0.65) 0.053
OBSERVANT −0.31 (−0.42, −0.20) 0.39 (0.25, 0.53) 0.57 (0.54, 0.60) 0.052
ACC TAVI 0.04 (−0.07, 0.15) 0.67 (0.52, 0.82) 0.64 (0.60, 0.67) 0.051
⁎ The reported calibration intercept is that estimated assuming a slope of one; satisfactory calibration would occur if the 95% confidence intervals for the calibration intercept and slope
span zero and one respectively. Bold items indicate that the 95% CI spans the corresponding reference value.
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Table IX).
The performances of all the CPMs in each subgroup are
given in the supplementary material (Supplementary
Table X). The expected mortality from the ACC TAVI
model was significantly close to the observed mortality
across all strata, but satisfactory calibration (calibration
intercept and slope close to zero and one, respectively)
was only observed for this CPM in female and diabetic
subgroups. All other models were miscalibrated across
strata. The area under the ROC curve was below 0.7 for
all CPMs across the subgroups, with the majority close to
0.6; the ACC and FRANCE-2 CPMs had the highest
discrimination across subgroups.
Agreement analysis
The chosen cut-off values that gave approximately
equal numbers of patients in low-, medium-, and high-risk
categories are given in Table IV. Based on these cut-off
values, the proportions of patients classified in each risk
level who were similarly classified across the other CPMs
were calculated (Figure 2 for the surgical based CPMs and
Figure 3 for the TAVI based CPMs). A low level of
agreement at an individual patient level was observed; for
example, only 31.8% of the 1951 patients grouped ashigh-risk by FRANCE-2 N10% were also grouped as high-
risk by the OBSERVANT and ACC models (Figure 3).
Quantifying agreement between the CPMs using Fleiss's
κ, highlighted that agreement between all the surgical
scores was moderate (κ=0.37), while that between all
the TAVI models was poor (κ=0.20). The pairwise
Fleiss's κ values are given in Table IV, which shows that
there was moderate agreement between the FRANCE-2
and ACC TAVI models (κ=0.33). Risk stratifications were
re-defined to give a population ratio of approximately
1:3:1 for low, medium, and high risk. Here, the results
indicated marginally improved levels of agreement, but
these were still moderate. Specifically, the Fleiss's κ
across the surgical scores was 0.40 and that between the
TAVI models was 0.20, with pairwise Fleiss's κ values
given in Supplementary Table XI.Discussion
Clinical prediction models form the cornerstone of risk
stratification for patients undergoing invasive proce-
dures, helping to guide both treatment allocation and
the consent process. However, their performance needs
to be tested in large datasets independent to those in
which the models were developed before they can be
Figure 2
The proportion of patients that agree in risk allocation over the surgical based CPMs. Each bar represents a risk stratification by one of the surgical
CPMs, with the segments of that bar showing the proportion of patients that were also grouped in that risk strata by none, one or both of the other
surgical CPMs.
Figure 3
The proportion of patients that agree in risk allocation over the TAVI based CPMs. Each bar represents a risk stratification by one of the TAVI-CPMs,
with the segments of that bar showing the proportion of patients that were also grouped in that risk strata by none, one or both of the other TAVI-
CPMs.
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TAVI registry has systematically demonstrated that
outside their development cohorts, the German AV,
FRANCE-2, OBSERVANT and ACC TAVI CPMs are
miscalibrated and have low discrimination at predicting
30-day mortality. These results support previous work in
this area.28 In the current study, the FRANCE-2 and ACC
models had the highest discrimination out of all those
considered, with these comparing favorably to theinternal validation results reported when these models
were derived.14,15 In addition, although the ACC model
was miscalibrated, the expected mortality was signifi-
cantly close to the observed mortality across all
subgroups considered in this analysis. However, of note
is that the ACC model was predominately developed to
predict in-hospital mortality, which potentially contrib-
utes to the agreement between the observed and
expected event rates for this model.
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they are applied in populations external to the develop-
ment set since patient mix and procedure techniques vary
between populations.26,27,29 Consequently, the findings of
the current study are, perhaps, unsurprising given that the
TAVI-CPMs achieved only moderate performance in their
respective development datasets.12,14,15 Current TAVI
cohorts predominantly represent a particularly high-risk
and homogenous group of patients, potentially contribut-
ing to the lack of a highly predictive TAVI-CPM. Future
TAVI-CPMs need to be developed by utilizing the
contemporary large registries that are emerging, which
will inevitably require greater harmonization between
variable and outcome definitions amongst national
datasets.
Moreover, many of the co-morbidities used in the
development of CPMs are cardiovascular risk factors, with
important non-cardiovascular co-morbidities not consid-
ered.30 In particular, frailty is not reflected in many of the
CPMs, despite being particularly prevalent in elderly patients
with aortic stenosis and previous work suggesting frailty to
be associated with poor TAVI outcomes.31,32 A CPM that
aims to predict long-term mortality following TAVI found
that the inclusion of frailty in their model significantly
increased the discrimination.33 Similarly, a previously
published CPM that aims to predict mortality and/or a
decline in quality of life following TAVI included an
indication of 6-minute walk test distance.34
The present study indicated that the 30-day mortality
was elevated in 2007 and 2008 over that in subsequent
years, but the sensitivity analysis that excluded 2007/08
procedures indicated similar results to the main analysis.
Previous studies have shown a learning curve associated
with TAVI, but center/operator volume and outcome
relationships remain debated.35-37 Nevertheless, mea-
sures of operator volume or experience are not used in
CPMs since accounting for such variables would be
inappropriate, particularly when the purpose of a CPM
might be to benchmark an individual operators/centers
performance. Similarly, the addition of operator volume/
experience in a CPMwould make it almost impossible for
a physician to convey the predicted risk to a patient.
Comparison with performance of the surgical CPMs
The current study confirms previous work in showing
that the performance of the LES, ESII and STS models are
poor at predicting 30-day mortality post TAVI.9-11 The STS
model outperformed the other surgical models, with the
STS expected 30-day mortality rate not significantly
different from the observed 30-day mortality rate. This
finding has been previously observed9,11 and is perhaps
attributable to the fact the STS score has a specific model
for isolated valve surgery.8 Of note, previous TAVI
registries have reported mean STS values higher than
that found in this study, perhaps due to the assumptions
made in our study regarding the calculation of the STSmodel. For example, the FRANCE TAVI registry reported
STS values of around 18%, while the Italian CoreValve
registry reported values of 11%.38,39
Nonetheless, comparing the surgical CPMs to the
TAVI-CPMs highlights that the latter performed better
than the former when internally validated12,14 and the
current study shows that the FRANCE-2 and ACC models
outperformed the surgical scores. Surgical CPMs are
limited in their use in transcatheter procedures because
they were derived from surgical populations. Not only are
the procedural risks of TAVI different from those in SAVR,
but there is lack of grading between the severities of
co-morbidities in the surgical CPMs. For example, chronic
obstructive pulmonary disease is a risk factor in LES, but
there is no further distinction between the severity of
chronic obstructive pulmonary disease or even other
severe lung disease. Since the heart-team considers such
severities when deciding between SAVR and TAVI, grading
of co-morbidities should be included in future TAVI-CPMs.
Patient-level agreement analysis
This study highlighted that the classification of patient
risk varies between multiple CPMs, even when comparing
surgical and TAVI based CPMs separately. A Pearson
correlation coefficient of 0.56has previously been reported
between the LES and STS score,10 with similar correlation
between these scores reported in other studies.11 Such an
analysis does not necessarily indicate the level of agree-
ment between two risk models, since the correlation is
only assessing the linear relationship between them.40
Although the current study found higher agreement
between the surgical models than between the TAVI
models, this was driven by the ESII being an updated
version of the LES. The lack of agreement between the
scores further highlights previously published recommen-
dations that risk assessment should be based on heart-team
discussion in combination with multiple CPMs.4
Limitations
A limitation of the current work is that assumptionswere
required when linking the definitions of model variables
with the TAVI dataset, as described in the supplementary
material. For example, the lowest LV function category in
the ESII model is LVEF b20% whereas that in the UK TAVI
dataset is LVEFb30%, with this analysis assuming these
definitions to be equivalent. Such assumptions are an
artifact of different recording practices between national
registries. Accordingly, some of the surgical CPMs could
not be calculated exactly as they were published, which
could induce bias into the calculated predicted risks. This
study used surrogate variables to mitigate this wherever
possible and all assumptions weremade to reflect the TAVI
procedure as accurately as possible. As noted above, the
calculated STS score in this study is lower than previously
reported from other TAVI registries. Lack of variables
including mitral valve, hypertension and severity of
104 Martin et al
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findings compare favorably to previouswork. Similarly, the
assumption of risk factor absent for variables that were
included in CPMs but not recorded in the UK TAVI registry
(eg, mitral valve replacement or infective endocarditis)
may induce bias, but any such bias is likely to be negligible
given the variables where this assumption was needed.
Implications for future work
Based on this work, the development of further
TAVI-CPMs is recommended in populations of interest.
Although there is an indication of the feasibility of TAVI in
intermediate risk patients,5 TAVI-CPMs are still required,
especially for procedure audit purposes and risk stratifi-
cation analyses. Rather than developing new scores from
scratch, model updating techniques could be applied to
the current TAVI-CPMs to adapt them to new national
cohorts.41 For instance, re-fitting the current models to
the population of interest and/or the addition of new risk
factors, such as frailty, could improve prediction.31,42
Further work in this area is recommended. Secondly,
developing TAVI models that predict both short- and
long-term outcomes would be particularly valuable,
especially if they included a measure of futility.Conclusions
The FRANCE-2 and ACC TAVI models had the highest
performance across all CPMs considered. However, all the
CPMs had low calibration and discrimination, reducing
their suitability for risk stratification outside their develop-
ment cohorts. Future iterations of existing TAVI models
may benefit from including non-cardiovascular
co-morbidities such as frailty. The derivation of
TAVI-CPMs in contemporary large registries is recommend-
ed, but it remains to be determined if this is best achieved
by updating/revising existing TAVI scores, by developing
newCPMs in specific cohorts, or a combination of the two.Acknowledgements
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